Lundbeck Abandons Alzheimer's Med

Feb 09, 2017

Reuters

After two failed late-stage clinical trials, Lundbeck has called it quits on its experimental Alzheimer's drug.

The Denmark-based drugmaker said the trials for its idalopirdine "do not demonstrate efficacy to support a regulatory submission."

The 5-HT6 antagonist was aimed at treating symptoms of the brain disorder, rather than halting progression of the underlying disease. U.S.-based rival Axovant Sciences is developing similar 5-HT6 antagonist drug called intepirdine.

Read the Reuters coverage